Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Personal Side of COVID-19: A Q&A with Elna Schiopu, MD

Kurt Ullman  |  December 14, 2020

Elna Schiopu, MD, is a rheumatologist who has been in practice for nearly 15 years. She is affiliated with University of Michigan Hospitals & Health Center and an associate professor of internal medicine/rheumatology at the University of Michigan Medical School, Ann Arbor, Mich.

Dr. Schiopu has experienced the COVID-19 pandemic response from both clinical and research perspectives. She recently discussed her experiences with The Rheumatologist (TR).

Dr. Schiopu

TR: What lessons have you learned from the pandemic?
Dr. Schiopu: The question is complex, and this situation is unprecedented. There are several layers around COVID-19 knowledge, starting with the naked data surrounding what happened, such as structure of the virus, its transmission, its mortality, etc. The next layer is the different perspectives [on] interpreting the data—epidemiologist, infectious disease experts, etc. The following layer is the media and the spinning by both traditional and online media in their presentation of the facts. The last—and probably biggest layer—is how do we interpret [the data], and how we adjust to what is happening from a family, physician, immunology perspective.

TR: How did your practice change to meet the demands of the pandemic?
Dr. Schiopu: My feeling was incredible frustration. It’s like when patients bring me a bottle with a supplement, hand it to me and ask if it is safe. The problem is we have very minimal data on what is in it—let alone its safety.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

I [have] felt the same through most of the pandemic. Patients are told to ask your doctor, but what do we know? Having no data is almost better than so much contradictory data. As a physician with patients who have family and friends calling us and asking what to do, it was frustrating to say the least.

New patient access became complex because everything was shut down. When patients were sick, there was no hesitation. We were able to convey to our patients the need for them to start immunosuppressive drugs and not wait for the pandemic to end.

What hindered me—and I am beyond furious—was state government interference in our medical practice. There was a time when the governor of Michigan—who does not hold a medical license—banned doctors from prescribing hydroxychloroquine for COVID-19. This [decision] created a lot of hoops for prescribing this medication to non-COVID patients.

In addition, the lengthy, statewide strict lockdowns spread fear and distrust among our patients without seemingly helping in any way with transmission of the virus. At times, I felt advocating for our patients could result in professional backlash, because we still had (have) to keep up the narrative that this virus kills everyone in its path—which we are learning is far from being true.

Page: 1 2 3 | Single Page
Share: 

Filed under:Professional Topics Tagged with:COVID-19telemedicine

Related Articles

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

    July 6, 2021

    Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

    The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine

    March 17, 2020

    In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences